Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

1457 ET -- Bristol-Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Shares were recently up 11% after AbbVie ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Bristol-Myers Squibb Up Over 11%, on Pace for Largest Percent Increase Since March 2000 — Data Talk Bristol-Myers Squibb Company (BMY) is currently at $60.49, up $6.35 or 11.73% --Would be highest ...

Bristol Myers (BMY) is up 11.6%, or $6.29 to $60.43. Published first on TheFly – the ultimate source for real-time, market-moving ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Purchased royalties on Pharvaris' deucrictibant in Phase 3 development for hereditary angioedema. FDA granted approvals for Bristol Myers Squibb's Cobenfy (formerly KarXT) for schizophrenia, Johnson ...